U.S. Stock Market Midday Update
Inspire Medical fell 16.53%, with increased trading volume. Based on recent news,
<ol>
<li>
On December 16, Inspire Medical announced that the company is facing multiple securities lawsuits, which has shaken investor confidence in the company's future, leading to a significant drop in stock price. According to the announcement, the lawsuits involve the company's securities trading activities from August 6, 2024, to August 4, 2025, and investors are encouraged to contact relevant law firms for more information.
</li>
<li>
On December 17, multiple investment banks raised their target prices for Inspire Medical. Mizuho raised its target price from $110 to $130, and JP Morgan raised its target price from $82 to $118. However, these positive ratings failed to offset market concerns regarding the company's lawsuits, and the stock price continued to decline.
</li>
<li>
On December 17, the securities lawsuits against Inspire Medical further escalated, with several law firms issuing announcements encouraging investors to participate in class action lawsuits. Investors are worried that the lawsuits could lead to substantial compensation for the company, further depressing the stock price. The overall performance of the medical industry has been weak recently, and investors should exercise caution.
</li>
</ol>
Top Stocks by Industry Trading Volume
Boston Scientific rose 2.34%. Based on recent news,
<ol>
<li>
On December 18, RBC Capital raised its target price for Boston Scientific from $125 to $130 and maintained an &#34;Outperform&#34; rating. This positive analyst rating boosted market confidence, driving the stock price up.
</li>
<li>
On December 17, RBC Capital released a report announcing the increase of Boston Scientific's target price to $130. This news further enhanced investor confidence in the company, leading to a rise in stock price. Trading volume increased, and market confidence strengthened.
</li>
</ol>
Intuitive Surgical rose 1.36%. Based on recent news,
<ol>
<li>
On December 17, Intuitive Surgical executive Mark Brosius sold shares of the company's common stock. A total of 464 shares were sold in this transaction, amounting to $254,499. This news may have sparked market attention regarding insider stock changes, leading to stock price fluctuations.
</li>
<li>
On December 15, Intuitive Surgical Vice President Brosius Mark submitted Form 4, disclosing his stock trading activities from December 12 to December 15. During this period, he exercised options for 4,500 shares and sold 4,964 shares of common stock according to a predetermined trading plan, with a total value of approximately $2,717,619. This series of transactions may have impacted market sentiment.
</li>
<li>
On December 16, analysts adjusted their ratings for Intuitive Surgical. An analyst from Citigroup downgraded the rating to Neutral and adjusted the target price to $635. This rating adjustment may have a negative impact on investor confidence. The overall market is experiencing significant volatility, and investors should exercise caution
Stryker rose 1.72%. Based on recent news,
</li>
<li>
On December 17, Stryker's Vice President Fink M Kathryn and Berry William E Jr repurchased 37 and 28 shares of the company, respectively, to cover option exercise costs and tax liabilities. This insider trading demonstrates the confidence of the company's executives in its future development, boosting market sentiment and driving up the stock price.
</li>
<li>
On December 17, MarketBeat released a report indicating that although Stryker currently holds a &#34;Moderate Buy&#34; rating among analysts, top analysts believe there are five stocks that are more worthy of investment. This news may have had a negative impact on some investors, but the overall market reaction was relatively mild.
</li>
<li>
On December 18, market attention on Stryker increased, with trading volume significantly expanding to $162 million. This indicates growing investor interest in the stock, further driving up the stock price. Recently, there has been increased market focus on the medical device industry, with noticeable capital inflows.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Abbott fell 0.22%. Based on recent news:
<ol>
<li>
On December 18, Abbott's Amplatzer Piccolo™ delivery system received FDA approval and CE certification for optimizing treatment procedures for congenital heart defects in premature infants. This approval may enhance Abbott's market competitiveness in the medical device field, driving stock price volatility.
</li>
<li>
On December 16, MarketBeat reported that although Abbott currently holds a Moderate Buy rating from analysts, top analysts believe there are five stocks with greater investment value. This may lead to a weakening of investor confidence in Abbott, affecting stock performance.
</li>
<li>
On December 17, Michigan State University developed human heart organoids, providing a new model for heart disease research. This breakthrough may have an indirect impact on Abbott's development of heart-related products, increasing market attention. Competition in the medical device industry is intensifying, and policy changes should be monitored
</li>
</ol>

INSP

Inspire Medical fell 16.53%; Boston Scientific rose 2.34%, with a transaction volume of USD 597 million; Intuitive Surgical rose 1.36%, with a transaction volume of USD 214 million; Stryker rose 1.72%, with a transaction volume of USD 162 million; Abbott fell 0.22%, with a market value of USD 219.8 billion

U.S. stock market midday update: Inspire Medical faces multiple lawsuits, stock price plummets 16.53%